Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: A case report with a 10-year follow-up

Bertrand Routy, Mohamed Rachid Boulassel, Gwendoline M. Spurll, Margaret N. Warner, Jean Pierre Routy

Research output: Contribution to journalArticle

2 Citations (Scopus)


Immune thrombocytopenia (ITP) is an autoimmune disease characterized by isolated low platelet counts often leading to mucocutaneous bleeding. Administration of rituximab was shown to increase platelet counts in patients relapsing chronic ITP. However, duration of response with rituximab and the long-term benefit remains unknown. Herein, the authors presented a case of a 36-year-old splenectomised man with a relapsing ITP who received a total of 10 cycles of rituximab over the last decade with the concomitant assessments of circulating B cells. The data show that rituximab can be an effective therapy over 10 years, and monitoring B cells may help to herald ITP recurrence.

Original languageEnglish
Pages (from-to)219-222
Number of pages4
JournalAmerican Journal of Therapeutics
Issue number2
Publication statusPublished - Mar 2013



  • B cells
  • Immune thrombocytopenia
  • Platelets
  • Rituximab

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this